HMG-CoA reductase inhibitor mediates the JAK/STAT3 pathway to improve vascular endothelial function impairment in elderly patients with essential hypertension
TG
ESSENTIAL HYPERTENSION
From the aforesaid clinical trials and related articles [To test this hypothesis, we treated SHR rats with an HMG-CoA reductase inhibitor (atorvastatin calcium) and a JAK/STAT pathway inhibitor (AG490). The blood pressure levels (SBP and DBP), lipid levels (TC, TG, LDL-C, and HDL-C), cardiac function-related indices (LVIDd, LVIDs, LVEF, and LVFS), LVMI, serum inflammatory factor levels (IL-6, TNF-α, and hs-CRP), and vascular endothelial function indices levels (ET, NO, and eNOS) were evaluated. Compared with the normal group, there exhibited elevated levels of SBP, DBP, TC, TG, LDL-C, LVIDd, LVIDs, LVMI, IL-6, TNF-α, hs-CRP, and ET, and reduced levels of HDL-C, LVEF, LVFS, NO, and eNOS in the model group (all 
HMG-CoA reductase inhibitor mediates the JAK/STAT3 pathway to improve vascular endothelial function impairment in elderly patients with essential hypertension. Furthermore, the protein expression levels of JAK/STAT pathway-related factors in each group were tested by western blot (Fig. 